DRUG

SGLT2 inhibitors

2 hypotheses across 1 therapeutic domain

ALL HYPOTHESES

Repurposing candidates for SGLT2 inhibitors

Pancreatic cancer 2

Mediator Outcome Score Tier Lit. status Trial
SGLT2 prostate adenocarcinoma 0.264 Mid novel signal none
SGLT2 pancreatic adenocarcinoma 0.264 Mid partial evidence none

Clinical trials

200 registered trials for SGLT2 inhibitors

Source: ClinicalTrials.gov

← All drugs